66.90
Astrazeneca PLC 주식(AZN)의 최신 뉴스
Malignant Pleural Mesothelioma Market Poised for Growth Across the 7MM During the Study Period (2020–2034) Amid Advances in Immunotherapy and Targeted Drugs | DelveInsight - GlobeNewswire Inc.
Press Release Distribution & PR Platform - ACCESS Newswire
Omeprazole Market Is Booming Worldwide 2025-2032 | Astrazeneca Plc., Sandoz, Inc., Mylan N.V. - openPR.com
Should You Buy, Sell Or Hold AstraZeneca Stock Before Q1 Earnings? - Barchart.com
AstraZeneca's Enhertu, pertuzumab combo improves breast cancer treatment in trial - Seeking Alpha
Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings? - Yahoo
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients - Yahoo Finance
ENHERTU Plus Pertuzumab Demonstrated Highly Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival Versus. THP As 1st-Line Therapy For Patients With HER2+ Metastatic Breast Cancer - marketscreener.com
AstraZeneca (AZN) Highlights Promising Trial Results for Enhertu in Breast Cancer Treatment | AZN Stock News - GuruFocus
AstraZeneca Touts Positive Survival Data for Enhertu Combo in Broad Breast Cancer Population - marketscreener.com
AstraZeneca, Daiichi Sankyo's Breast Cancer Drug Shows High-level Results in Late-stage Trial - marketscreener.com
Vasculitis Market Overall Study Report 2025-2032 | AstraZeneca - openPR.com
AstraZeneca Unit Hit With Antitrust Suit Over Soliris - Law360
AstraZeneca Subsidiary Accused of Soliris Drug Market Monopoly - Bloomberg Law News
AstraZeneca unit sued over alleged monopoly on blockbuster drug Soliris - Reuters
AstraZeneca Unit Faces US Class Action Lawsuit Alleging Misuse of Soliris Patent - marketscreener.com
AstraZeneca Should Get Fired Worker’s Vaccine Bias Case Trimmed - Bloomberg Law News
BNP Paribas Exane sets AstraZeneca stock to outperform, PT at GBP115 - Investing.com UK
Is AstraZeneca PLC (AZN) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey
European pharma companies issue demands to stay in EU ahead of expected US tariffs - MarketScreener
Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly - insights.citeline.com
AstraZeneca Pharma India surrenders marketing authorisation for specific indication of Olaparib - Medical Dialogues
Is AstraZeneca (AZN) The Best UK Stock to Buy According to Billionaires? - Yahoo Finance
The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis - Nasdaq
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
AstraZeneca : India's Serum Institute asks government for $403 million to boost AstraZeneca vaccine output - marketscreener.com
NICE recommends new combination breast cancer drug - MarketScreener
astrazeneca shareholders approve all resolutions at agm - Investing.com
Astrazeneca PLC Says All Resolutions Passed At AGM - MarketScreener
AstraZeneca’s AGM Approves All Resolutions, Marks Board Changes - TipRanks
Drug Tariffs Will Harm Patients, AstraZeneca Chairman Says - Bloomberg.com
AstraZeneca (AZN) Gains Momentum with EU Drug Approvals - GuruFocus
AstraZeneca's quarterly earnings may undershoot; tariffs and a trade war pose the bigger obstacle - Proactive financial news
AstraZeneca and GSK retain defensive qualities, but tariff assault on sector could change that - Proactive Investors
GLP-1 Market Top PlayersAstraZeneca, Biolingus, Boehringer Ingelheim, D&D Pharmatech. - openPR.com
Down 28% in 8 months, is AstraZeneca’s share price too cheap for me to pass up right now? - Yahoo
AstraZeneca (AZN) Gains EU Nod for Imfinzi Combo in NSCLC Treatm - GuruFocus
AstraZeneca (AZN) Gains EU Approval for Expanded Enhertu Use in Breast Cancer - GuruFocus
AstraZeneca Settles Covid-Shot Suit With Christian Salesman - Bloomberg Law News
AstraZeneca Blocks Generics Ahead Of Patent Dispute - Law360
Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today - Mitrade
AstraZeneca stock touches 52-week low at $61.76 - Investing.com
AstraZeneca stock touches 52-week low at $61.76 By Investing.com - Investing.com India
UK Regulator Approves Expanded Use of AstraZeneca's Targeted Cancer Therapy - MarketScreener
UK Approves Indication Extension for AstraZeneca-Daiichi Sankyo's Cancer Drug Enhertu - marketscreener.com
Barclays Keeps AstraZeneca at Overweight on Potential to Withstand Tariff Storm - MarketScreener
AstraZeneca (AZN) Prepares for Upcoming Earnings Amid Stock Decl - GuruFocus
Trending tickers: Apple, Advanced Micro Devices, Ford, BP and AstraZeneca - Yahoo
FTSE 100 sinks as tariffs kick in with 104% for China; AstraZeneca and GSK slumpMarket Report - Proactive financial news
AstraZeneca's Camizestrant Shows Promise in SERENA-6 Breast Canc - GuruFocus
Trump inflicts £14bn blow to the UK drug sector with tariff threat - Proactive Investors
Astrazeneca (AZN) Stock Moves -1.35%: What You Should Know - Yahoo Finance
Daiichi Sankyo and AstraZeneca get EU approval for Datroway - Seeking Alpha
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
Relative Strength Alert For AstraZeneca - Nasdaq
자본화:
|
볼륨(24시간):